{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:34:31Z","timestamp":1791304471951,"version":"4.3.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"DOI":"10.7759\/cureus.81108","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T02:16:59Z","timestamp":1742869019000},"source":"Crossref","is-referenced-by-count":1,"title":["Role of B-Cell Inhibition in Autoimmune Hepatitis: Lessons Learnt From Systemic Lupus Erythematosus"],"prefix":"10.7759","author":[{"given":"Shivangini","family":"Duggal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrilekha","family":"Sairam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack CL","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, et al.. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020, 72:671-722. 10.1002\/hep.31065","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015, 63:971-1004. 10.1016\/j.jhep.2015.06.030","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.4103\/0019-5154.190107","article-title":"Belimumab in systemic lupus erythematosus","volume":"61","author":"Srivastava A","year":"2016","unstructured":"Srivastava A. Belimumab in systemic lupus erythematosus. Indian J Dermatol. 2016, 61:550-3.","journal-title":"Indian J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2019.1603324","article-title":"Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting","volume":"48","author":"Anjo C","year":"2019","unstructured":"Anjo C, Mascar\u00f3 JM Jr, Espinosa G, Cervera R. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol. 2019, 48:469-73. 10.1080\/03009742.2019.1603324","journal-title":"Scand J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100123","article-title":"Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis","volume":"2","author":"Arvaniti P","year":"2020","unstructured":"Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, Dalekos GN. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep. 2020, 2:100123. 10.1016\/j.jhepr.2020.100123","journal-title":"JHEP Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair HA","year":"2018","unstructured":"Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018, 78:355-66. 10.1007\/s40265-018-0872-z","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i35.12662","article-title":"Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature","volume":"20","author":"Beisel C","year":"2014","unstructured":"Beisel C, Weiler-Normann C, Teufel A, Lohse AW. Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World J Gastroenterol. 2014, 20:12662-7. 10.3748\/wjg.v20.i35.12662","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.03.023","article-title":"Towards personalised medicine in autoimmune hepatitis: measurement of thiopurine metabolites results in higher biochemical response rates","volume":"75","author":"Candels LS","year":"2021","unstructured":"Candels LS, Rahim MN, Shah S, Heneghan MA. Towards personalised medicine in autoimmune hepatitis: measurement of thiopurine metabolites results in higher biochemical response rates. J Hepatol. 2021, 75:324-32. 10.1016\/j.jhep.2021.03.023","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5895.20.02805-6","article-title":"Open challenges in the management of autoimmune hepatitis","volume":"69","author":"Gerussi A","year":"2023","unstructured":"Gerussi A, Halliday N, Carbone M, Invernizzi P, Thorburn D. Open challenges in the management of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2023, 69:61-83. 10.23736\/S2724-5895.20.02805-6","journal-title":"Minerva Gastroenterol Dietol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100601","article-title":"Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis","volume":"4","author":"Dalekos GN","year":"2022","unstructured":"Dalekos GN, Arvaniti P, Gatselis NK, et al.. Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis. JHEP Rep. 2022, 4:100601. 10.1016\/j.jhepr.2022.100601","journal-title":"JHEP Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago P","year":"2019","unstructured":"Santiago P, Schwartz I, Tamariz L, Levy C. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2019, 49:830-9. 10.1111\/apt.15157","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15248","article-title":"Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels","volume":"49","author":"Nicoll AJ","year":"2019","unstructured":"Nicoll AJ, Roberts SK, Lim R, et al.. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther. 2019, 49:1314-22. 10.1111\/apt.15248","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091346","article-title":"Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story","volume":"11","author":"Naffouje R","year":"2019","unstructured":"Naffouje R, Grover P, Yu H, et al.. Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story. Cancers (Basel). 2019, 11:1346. 10.3390\/cancers11091346","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou K","year":"2016","unstructured":"Zachou K, Gatselis N, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, Dalekos GN. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther. 2016, 43:1035-47. 10.1111\/apt.13584","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.798602","article-title":"First results from a propensity matching trial of mycophenolate mofetil vs. azathioprine in treatment-na\u00efve AIH patients","volume":"12","author":"Dalekos GN","year":"2022","unstructured":"Dalekos GN, Arvaniti P, Gatselis NK, et al.. First results from a propensity matching trial of mycophenolate mofetil vs. azathioprine in treatment-na\u00efve AIH patients. Front Immunol. 2022, 12:798602. 10.3389\/fimmu.2021.798602","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.35248\/2161-1149.19.9.247","article-title":"Good response of lupus hepatitis to mycophenolate mofetil and belimumab as of lupus exanthema to rituximab: a case report","volume":"9","author":"Psenak O","year":"2019","unstructured":"Psenak O, Studnicka A, Haufe H, Greil R. Good response of lupus hepatitis to mycophenolate mofetil and belimumab as of lupus exanthema to rituximab: a case report. Rheumatology (Sunnyvale). 2019, 9:247. 10.35248\/2161-1149.19.9.247","journal-title":"Rheumatology (Sunnyvale)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100189","article-title":"Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series","volume":"6","author":"Kolev M","year":"2023","unstructured":"Kolev M, Sarbu AC, M\u00f6ller B, Maurer B, Kollert F, Semmo N. Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series. J Transl Autoimmun. 2023, 6:100189. 10.1016\/j.jtauto.2023.100189","journal-title":"J Transl Autoimmun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05853-7","article-title":"Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion","volume":"9","author":"Nguyen DC","year":"2018","unstructured":"Nguyen DC, Garimalla S, Xiao H, et al.. Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. Nat Commun. 2018, 9:3698. 10.1038\/s41467-018-05853-7","journal-title":"Nat Commun"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16574","article-title":"Review article: targeting the B cell activation system in autoimmune hepatitis","volume":"54","author":"Czaja AJ","year":"2021","unstructured":"Czaja AJ. Review article: targeting the B cell activation system in autoimmune hepatitis. Aliment Pharmacol Ther. 2021, 54:902-22. 10.1111\/apt.16574","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003194","article-title":"B-cell activating factor belonging to the tumor necrosis factor family and interferon-\u03b3-inducible protein-10 in autoimmune hepatitis","volume":"95","author":"Nishikawa H","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al.. B-cell activating factor belonging to the tumor necrosis factor family and interferon-\u03b3-inducible protein-10 in autoimmune hepatitis. Medicine (Baltimore). 2016, 95:e3194. 10.1097\/MD.0000000000003194","journal-title":"Medicine (Baltimore)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2007.03.010","article-title":"Elevated serum BAFF levels in patients with autoimmune hepatitis","volume":"68","author":"Migita K","year":"2007","unstructured":"Migita K, Abiru S, Maeda Y, et al.. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol. 2007, 68:586-91. 10.1016\/j.humimm.2007.03.010","journal-title":"Hum Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/0891693021000066333","article-title":"Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes","volume":"35","author":"Mackay IR","year":"2002","unstructured":"Mackay IR, Groom J, Mackay CR. Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity. 2002, 35:551-3. 10.1080\/0891693021000066333","journal-title":"Autoimmunity"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/317826-role-of-b-cell-inhibition-in-autoimmune-hepatitis-lessons-learnt-from-systemic-lupus-erythematosus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T02:17:08Z","timestamp":1742869028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/317826-role-of-b-cell-inhibition-in-autoimmune-hepatitis-lessons-learnt-from-systemic-lupus-erythematosus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.81108","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}